{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:49:17Z","timestamp":1791524957764,"version":"4.3.4"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lana.2026.101575","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:50:19Z","timestamp":1785261019000},"page":"101575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Modernizing renal eligibility in oncology trials"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1200-9095","authenticated-orcid":false,"given":"Harold Nathan","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreedhar","family":"Mandayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabir","family":"Roy-Chaudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-3309","authenticated-orcid":false,"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lana.2026.101575_bib1","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"9","key":"10.1016\/j.lana.2026.101575_bib2","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1111\/bcp.13647","article-title":"Comparison of the Cockcroft\u2013Gault, MDRD and CKD-EPI equations for estimating ganciclovir clearance","volume":"84","author":"Palacio-Lacambra","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.lana.2026.101575_bib3","doi-asserted-by":"crossref","first-page":"861","DOI":"10.34067\/KID.0000000736","article-title":"Update on the assessment of GFR in patients with cancer","volume":"6","author":"Costa","year":"2025","journal-title":"Kidney360"},{"issue":"6","key":"10.1016\/j.lana.2026.101575_bib4","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney Int"},{"issue":"4S","key":"10.1016\/j.lana.2026.101575_bib5","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.lana.2026.101575_bib6","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2215\/CJN.0000000000000508","article-title":"Assessment of GFR in patients with cancer: a statement from the American society of onco-nephrology","volume":"19","author":"Kitchlu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.lana.2026.101575_bib7","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/14737159.2020.1768849","article-title":"Cystatin C as a biomarker of chronic kidney disease: latest developments","volume":"20","author":"Benoit","year":"2020","journal-title":"Expert Rev Mol Diagn"},{"issue":"12","key":"10.1016\/j.lana.2026.101575_bib8","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1681\/ASN.2021070988","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney diseases","volume":"32","author":"Delgado","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lana.2026.101575_bib9","series-title":"Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies. Guidance for Industry","year":"2020"},{"key":"10.1016\/j.lana.2026.101575_bib10","series-title":"Cancer clinical trial eligibility criteria: laboratory values\u2014guidance for industry","year":"2024"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X2600205X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X2600205X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:54:21Z","timestamp":1791521661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X2600205X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"alternative-id":["S2667193X2600205X"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2026.101575","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modernizing renal eligibility in oncology trials","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2026.101575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101575"}}